These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 7144360)

  • 21. Biomarkers to monitor drug-induced phospholipidosis.
    Baronas ET; Lee JW; Alden C; Hsieh FY
    Toxicol Appl Pharmacol; 2007 Jan; 218(1):72-8. PubMed ID: 17156806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug-induced phospholipidosis is caused by blockade of mannose 6-phosphate receptor-mediated targeting of lysosomal enzymes.
    Ikeda K; Hirayama M; Hirota Y; Asa E; Seki J; Tanaka Y
    Biochem Biophys Res Commun; 2008 Dec; 377(1):268-74. PubMed ID: 18840403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biomarker discovery for drug-induced phospholipidosis: phenylacetylglycine to hippuric acid ratio in urine and plasma as potential markers.
    Kamiguchi H; Murabayashi M; Mori I; Horinouchi A; Higaki K
    Biomarkers; 2017 Mar; 22(2):178-188. PubMed ID: 27775443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug-induced generalized phospholipidosis.
    Shikata T; Kanetaka T; Endo Y; Nagashima K
    Acta Pathol Jpn; 1972 Aug; 22(3):517-31. PubMed ID: 4678598
    [No Abstract]   [Full Text] [Related]  

  • 25. Urinary metabolic fingerprinting for amiodarone-induced phospholipidosis in rats using FT-ICR MS.
    Hasegawa M; Takenaka S; Kuwamura M; Yamate J; Tsuyama S
    Exp Toxicol Pathol; 2007 Oct; 59(2):115-20. PubMed ID: 17719757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cell-based fluorescence assay for evaluation of new-drugs potential for phospholipidosis in an early stage of drug development.
    Fujimura H; Dekura E; Kurabe M; Shimazu N; Koitabashi M; Toriumi W
    Exp Toxicol Pathol; 2007 Aug; 58(6):375-82. PubMed ID: 17408938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Phospholipidosis caused by diethylaminoethoxyhexestrol].
    Matsuda Y; Ikegami F; Kobayashi K; Hasumura Y; Takada A
    Saishin Igaku; 1971 Nov; 26(11):2263-7. PubMed ID: 5141969
    [No Abstract]   [Full Text] [Related]  

  • 28. Drug-induced lipidosis in human cases and in animal experiments. Accumulation of an acidic glycerophospholipid.
    Yamamoto A; Adachi S; Kitani T; Shinji Y; Seki K
    J Biochem; 1971 Mar; 69(3):613-5. PubMed ID: 5551653
    [No Abstract]   [Full Text] [Related]  

  • 29. [Case of phospholipidosis considered to be caused by orally administered diethylaminoethoxyhexestrol(DH)].
    Takino T; Sakai Y; Shinraku M; Tanizawa Y; Hashimoto S
    Saishin Igaku; 1971 Nov; 26(11):2241-2. PubMed ID: 5141965
    [No Abstract]   [Full Text] [Related]  

  • 30. [Phospholipidosis induced by chlorimipramine in rat lung].
    Gremigni D; Vannelli G; Sgaragli GP; Mengazzini I
    Boll Soc Ital Biol Sper; 1980 May; 56(10):1078-82. PubMed ID: 7448010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinico-pathological studies on 7 cases suspected to have phospholipidosis and epidemiological studies on 116 cases given diethylaminoethoxyhexestrol(DH)].
    Sasaki H; Tanaka S; Kimura K; Ichida F
    Saishin Igaku; 1971 Nov; 26(11):2230-6. PubMed ID: 5141963
    [No Abstract]   [Full Text] [Related]  

  • 32. Validation of an in vitro screen for phospholipidosis using a high-content biology platform.
    Morelli JK; Buehrle M; Pognan F; Barone LR; Fieles W; Ciaccio PJ
    Cell Biol Toxicol; 2006 Jan; 22(1):15-27. PubMed ID: 16463016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [New forms of toxic hepatitis. 3. Lipidosis (phospholipidosis), a new form of drug induced liver damage].
    Markoff N
    Hippokrates; 1973 Dec; 44(4):455-7. PubMed ID: 4779552
    [No Abstract]   [Full Text] [Related]  

  • 34. Myopathy related to administration of a cationic amphiphilic drug and the use of multidose drug distribution analysis to predict its occurrence.
    Vonderfecht SL; Stone ML; Eversole RR; Yancey MF; Schuette MR; Duncan BA; Ware JA
    Toxicol Pathol; 2004; 32(3):318-25. PubMed ID: 15204973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. X-ray microanalysis of cultured alveolar macrophages with phospholipidosis.
    Lee P; Kirk RG; Reasor MJ
    Exp Mol Pathol; 1993 Apr; 58(2):96-104. PubMed ID: 8388333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening for the drug-phospholipid interaction: correlation to phospholipidosis.
    Alakoskela JM; Vitovic P; Kinnunen PK
    ChemMedChem; 2009 Aug; 4(8):1224-51. PubMed ID: 19551800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Characteristics of lipoprotein metabolic disorders during treatment with oral contraceptives].
    Titov VN; Sanfirova VM; Khodakova TD
    Farmakol Toksikol; 1980; 43(3):345-8. PubMed ID: 7449976
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Iatrogenic phospholipidosis mimicking Fabry disease.
    Bracamonte ER; Kowalewska J; Starr J; Gitomer J; Alpers CE
    Am J Kidney Dis; 2006 Nov; 48(5):844-50. PubMed ID: 17060007
    [No Abstract]   [Full Text] [Related]  

  • 39. Inhibition of gentamicin-induced nephrotoxicity by lithium in rat.
    Samadian T; Dehpour AR; Amini S; Nouhnejad P
    Histol Histopathol; 1993 Jan; 8(1):139-47. PubMed ID: 8443425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Posaconazole-induced podocyte phospholipidosis.
    Gilani S; Nasr SH; Sethi S
    Kidney Int; 2022 Mar; 101(3):654. PubMed ID: 35190046
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.